secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001619856-24-000003
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou appoints Tim Kelly as CTO; plans CB-010 pivotal trial by YE 2024, cash into Q4 2025
--------------------------------------------------------------------------------

- Tim Kelly appointed CTO; previously CEO of Oxford Biomedica Solutions, led technical ops at Sarepta, Shire, and Biogen.
- $396.7M cash, cash equivalents, and marketable securities as of Sep 30, 2023; expected runway into Q4 2025.
- CB-010: initial dose expansion data from ANTLER trial and RP2D expected Q2 2024; Phase 3 pivotal in 2L LBCL by YE 2024.
- CB-011: initial dose escalation data from CaMMouflage trial expected by YE 2024.
- CB-012: patient enrollment in AMpLify Phase 1 trial for r/r AML expected to initiate H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000003/0001619856-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000003/crbu-20240107.htm
  HTML page:      https://secwatch.observer/filing/0001619856-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer